AI traction offsets a cooling ad market
- Doximity reaches more than 85% of U.S. physicians, which gives it a rare healthcare audience.
- Revenue growth reaccelerated to 7% in the first quarter of fiscal 2027, showing stabilization.
- The Clinical AI Suite has grown to 165 health systems, fueled by strong safety scores in independent studies.
- Large customers drive the business, with 127 clients over $500,000 accounting for 83% of total revenue.
- Net revenue retention fell to 107%, signaling limits to how much existing customers will expand their spend.
The network is strong, growth is stabilizing
Doximity owns a valuable place in U.S. healthcare. It has a massive registered user base and reaches more than 85% of U.S. physicians. That audience lets drug makers and health systems pay Doximity to reach doctors, hire doctors, and support doctor workflows.
The bull case focuses on artificial intelligence. Doximity has packaged Ask, Scribe, and Dialer into a Clinical AI Suite for enterprise clients. More than 165 U.S. health systems have signed up. Independent studies like NOHARM show Ask has an industry-low clinical error rate of 4.8%. This gives the company a real shot at selling into clinical workflow budgets instead of only ad budgets.
The bear case is that the core advertising market has cooled and AI costs are rising. While revenue growth reaccelerated to 7% in the first quarter of fiscal 2027 to reach $157 million, net revenue retention ticked down to 107%. Meanwhile, heavy compute investments for AI have pushed gross margins down slightly to 88%.
This is now a story about execution. Doximity is trying to prove that highly profitable early AI search monetization can scale up and offset softer digital advertising demand without breaking the bottom line.
Doctors use it, customers pay
Doximity gives many tools to doctors for free or as part of a health system package. Those tools include medical news, professional profiles, secure communication, telehealth, on-call scheduling, AI search, and AI note taking. The free use matters because it keeps doctors active on the platform.
The money comes mostly from subscription customers. In fiscal 2026, about 94% of revenue came from subscription customers. These customers are mainly pharmaceutical manufacturers and health systems buying Marketing Solutions, Hiring Solutions, and Workflow Solutions.
Early AI search tools are showing favorable unit economics, bringing in a return of more than ten times the compute cost. The model works best when drug companies shift marketing dollars to digital channels and health systems buy more workflow tools.
Customer concentration is a key part of the model. Just 127 large customers accounted for 83% of recent quarterly revenue. That helps sales efficiency, but it also means a small group of large buyers can move the overall results.
Ads fund the AI push
Marketing Solutions
Drug makers use Doximity to share targeted content with doctors. This is the core money maker, but demand has softened as pharma clients make shorter commitments.
Hiring Solutions
Health systems and other customers use Doximity to find and recruit medical professionals. It benefits from the physician network, but it is not the main growth debate.
Workflow Solutions
These products help doctors call patients, manage schedules, document visits, and use AI tools. The health system sale is becoming more important as Doximity moves beyond ads.
Clinical AI Suite
This bundles Ask, Scribe, and Dialer into one enterprise product. With 165 U.S. health systems signed on, it represents a major push into workflow budgets.
Ask
Ask is the AI clinical search and writing tool. Validated by the NOHARM study with a low 4.8% error rate, it uses a built-in drug reference and PeerCheck editors for safety.
Scribe
Scribe is an AI documentation tool for notes. It saves doctors time, but heavier use brings higher AI infrastructure costs.
Dialer
Dialer supports voice and video patient calls. It helps keep providers active in the daily workflow.
Mostly subscription revenue
Fiscal 2026 mix uses the company's disclosed revenue type, not product lines. Doximity says about 94% of revenue came from subscription customers and does not split Marketing, Hiring, and Workflow revenue.
What could go wrong
Pharma ad budgets stay soft
High impact · High oddsManagement previously noted short-term demand in the digital pharma ad market is soft. While revenue reaccelerated to 7% recently, Marketing Solutions may not sustain high growth if drug makers sign smaller deals.
Existing customer expansion weakens
High impact · Medium oddsNet revenue retention fell to 107% from 112% late last year and 119% in fiscal 2025. That means existing customers are still spending more, but the pace of expansion continues to slow.
AI errors damage trust
High impact · Medium oddsDoximity faces a high bar for security compliance. In medicine, an inaccurate AI answer or a leak of protected health information can cause legal, reputation, or adoption problems instantly.
Investment spending outruns payoff
Medium impact · Medium oddsThe company is in an active AI investment year. Gross margins compressed to 88% as compute costs scale with rapid clinician adoption. Heavy investment could pressure the bottom line if revenue ramps slowly.
In one breath
How does Doximity make money?
Doximity mostly sells subscriptions to pharmaceutical companies and health systems. Customers pay for Marketing Solutions, Hiring Solutions, and Workflow Solutions.
Why does Doximity have an AI story?
Doctors already use Doximity tools during their workday, so the company is adding AI into those workflows. Its Clinical AI Suite bundles Ask, Scribe, and Dialer for enterprise health systems.
What is the biggest debate for DOCS stock?
The debate is whether highly profitable early AI search monetization can offset softer digital advertising demand. First quarter fiscal 2027 revenue growth reaccelerated to 7%, but net revenue retention continues to fall.
